Press Releases
January 26, 2012
Drug Company Executives Are Expanding Their Use of Strategic Partnerships
Pharmaceutical and biopharmaceutical companies, under pressure to increase R&D productivity, are expanding their use of strategic partnerships to bring new drugs to market more quickly and at lower cost, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
Jan. 17, 2012
Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Asso
The Tufts Center for the Study of Drug Development today announced that it has established the first global benchmark for clinical research associate (CRA) workload and utilization, giving managers insights into improving CRA effectiveness and efficiency.
January 5, 2012
Drug Companies Are Taking Steps to Improve R&D Productivity
Although drug companies are pursuing innovative approaches to increase the pace and reduce the cost of drug development, the greatest advances will come from better coordination with development partners and improved clinical trial design, according to the Tufts Center for the Study of Drug Development.
Nov. 8, 2011
Number of Monoclonal Antibody Products in Development Continues to Increase
Developers are steadily increasing the number of monoclonal antibody products—known as mAbs—for which they are initiating clinical studies, extending a trend that began in the 1990s, according to the Tufts Center for the Study of Drug Development
October 6, 2011
Drug Companies Are Using Innovative Partnerships to Spur Development
Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative partnerships that are leading to, among other things, more molecular entities entering Phase I trials and shorter study times, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
Sept. 13, 2011
Majority of Clinical Trial Protocols Are Amended, But One-Third of Those Changes Are Avoidable
Nearly 60 percent of all protocols used in clinical trials for new drugs are amended during the trial. Moreover, one-third of those changes could have been avoided, according to the first-ever analysis, conducted by the Tufts Center for the Study of Drug Development, quantifying the impact of protocol changes on clinical trials.
August 9, 2011
Management Implications of the Global Regulatory Environment
As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory complexity is forcing them to change the way they operate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
July 19, 2011
Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines
Lack of evidence that links diagnostic tests to health outcomes has led payers in the United States to be skeptical about the clinical usefulness of those tests and is hindering the growth of personalized medicines, according to a newly completed analysis by the Tufts Center for the Study of Drug Development.
May 10, 2011
Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade
U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of Drug Development, but drug developers "face substantial challenges" if they are to maintain that pace, the study's author says.
April 26, 2011
Drug Developers Actively Improving Efficiency of Clinical Trials
Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with investigative sites in developing protocols and educating patients about trials before they agree to participate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
March 8, 2011
U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily
New or modified indication approvals for existing prescription drugs have steadily increased in the United States since the late 1990s, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.
January 27, 2011
Translational Science Expected to Play a Growing Role in Creating New Drugs
To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to make decisions about what targets to pursue and how to allocate resources, according to a panel of pharmaceutical and biotech industry leaders and academics recently convened by the Tufts Center for the Study of Drug Development.
January 12, 2011
U.S. Healthcare Stakeholders Uncertain about Benefits of Risk Evaluation Program
Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about the benefits of a risk evaluation program introduced three years ago by the Food and Drug Administration (FDA), according to the Tufts Center for the Study of Drug Development.
November 16, 2010
Personalized Medicines Are Shaping the Way R&D Is Done, According to Tufts Center for the Study of Drug Development
Personalized medicine development, occupying a growing role in the clinical pipelines of drug developers, is leading companies to change their R&D paradigms, including how they make go/no-go decisions, according to a recently completed study by the Tufts Center for the Study of Drug Development.
October 26, 2010
Pharma and Biotech Firms Are Rethinking Their Approach to Outsourcing
The current business climate is challenging pharmaceutical and biotech companies to rethink their approach to outsourcing and how best to build alliances with external service providers as part of a long term drug development strategy, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.
September 9, 2010
Approval Success Rates Higher for Smaller Firms Among Top 50 Pharmaceutical Companies
The top 10 pharmaceutical companies out of the world's top 50 have lower estimated overall clinical approval success rates than do smaller firms in that group, but nonetheless appeared to have some R&D productivity advantages, according to a new study completed by the Tufts Center for the Study of Drug Development.
August 11, 2010
Portfolio Management Is Key to Improved Drug Development Productivity
Drug developers need to change the way they allocate resources for new product development, lifecycle management, and business development and licensing—collectively known as portfolio management—if they are to improve drug development productivity, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug
Development.
July 8, 2010
Comparative Effectiveness Research Could Alter Pharmaceutical Care in the United States
Comparative effectiveness research, which assesses the relative strengths and weaknesses of various medical interventions, could help close the gap between what is known and what is done in pharmaceutical care in the United States, according to the Tufts Center for the Study of Drug Development, which recently completed an analysis on the matter.
April 6, 2010
New Approaches to R&D May Prove Best Path for Drug Developers
Innovative approaches to drug development, including alliances and partnerships, may prove the best way to increase the rate at which the research–based drug industry brings new products to market, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.
March 11, 2010
Regulatory Affairs Workload at Drug Development Firms Has Increased Dramatically
A growing volume of global drug development and commercialization activity during the past decade has dramatically increased the workload for regulatory affairs professionals at pharmaceutical and biotech companies, according to a study recently completed by the Tufts Center for the Study of Drug Development.
January 28, 2010
Tufts Center for the Study of Drug Development Launches New Website
The Tufts Center for the Study of Drug Development, the world's leading, independent authority on the nature and pace of pharmaceutical and biotech drug development, today announced the launch of its new website that makes it easier for industry professionals and others to research critical drug development issues.
January 26, 2010
Capacity Planning Is Becoming a Critical Success Factor for Drug Developers
Growing pressure within the research-based drug industry to bring new products to market faster and more efficiently is transforming clinical trial capacity planning and forecasting from an important area of concern to a critical success factor.
January 20, 2010
U.S. Orphan Product Designations More than Doubled During Last Decade
The number of orphan product designations in the U.S. more than doubled during the last decade, reflecting growing interest by pharmaceutical and biotech companies in developing products to treat orphan diseases.
January 6, 2010
Drug Companies Still Under Pressure to Increase Pace of Development
Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success will depend on how well they partner with other firms at specific points on the development spectrum, according to the Tufts Center for the Study of Drug Development.
November 17, 2009
New Products to Treat Neglected Diseases Are on the Rise
New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as R&D funding for those diseases has increased.
September 9, 2009
Marketing Exclusivity for First -in-Class Drugs Has Shortened to 2.5 Years
Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades - from a median of 10.2 years in the 1970s to 2.5 years in the early part of this decade - underscoring the competitive nature of drug development, a new study recently completed by the Tufts Center for the Study of Drug Development has found.
July 8, 2009
Large Pharmaceutical Firms Are Getting More Drugs Into Development While Terminating Unpromising Candidates
Large pharmaceutical firms, under pressure to bring new medicines to market faster, have been getting more drug candidates into development in recent years and have become more aggressive in terminating unpromising candidates.
May 20, 2009
Number of Therapeutic Peptides in Clinical Study Has Nearly Doubled Since the 1990s
Since 2000, the number of therapeutic peptides in clinical study have nearly doubled the 1990s rate, due in part to advances in synthesis, delivery, and formulation technologies.